Erectile Dysfunction Drugs Market

Executive Summary

Erectile Dysfunction Drugs Market was valued at US $3,977.79 million in 2021 and is projected to grow at 8.02% CAGR over the forecast period to reach US $6,318.88 million by 2027. Erectile Dysfunction Drugs Market represented US $568.67 million opportunity over 2019-2021 and estimated to create US $2,341.08 million opportunity in 2027 over 2021.

Erectile Dysfunction Drugs from Consainsights analyses the Erectile Dysfunction Drugs Market in the Life Sciences industry over the forecast period to 2027.

Erectile Dysfunction Drugs research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Erectile Dysfunction Drugs segmentation includes Product, Distribution Channel and Geography.

Based on the Product, the Erectile Dysfunction Drugs analysis covers Viagra (sildenafil citrate), Cialis (Tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (Alprostadil Cream), Other Products.

In Product segment, Viagra (sildenafil citrate) segment has highest cagr growth of 7.10%.

Based on the Distribution Channel, the Erectile Dysfunction Drugs analysis covers Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

In Distribution Channel segment, Hospital Pharmacies segment has highest cagr growth of 7.10%.

Based on the region, the Erectile Dysfunction Drugs analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Apricus Biosciences Inc., Bayer AG, Eli Lilly and Company, Ferring Pharmaceuticals, GlaxoSmithKline PLC, Metuchen Pharmaceuticals LLC, Pfizer Inc., S.K. Chemicals Co. Ltd, Teva Pharmaceutical Industries Ltd, VIVUS Inc., Lupin Limited and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Viagra (sildenafil citrate) segment has the highest revenue of US $1,550.30 million and is expected to grow at CAGR of 7.10% by 2027 Viagra (sildenafil citrate) segment has highest cagr growth of 7.10%.

Viagra (sildenafil citrate)

Viagra (sildenafil citrate) segment was valued at US $1,328.67 million in 2019 and is projected to grow at 7.10% CAGR over the forecast period to reach US $2,462.71 million by 2027. Viagra (sildenafil citrate) segment represented US $221.63 million opportunity over 2019-2021 and estimated to create US $912.41 million opportunity in 2027 over 2021.

Cialis (Tadalafil)

Cialis (Tadalafil) segment was valued at US $881.84 million in 2019 and is projected to grow at 7.10% CAGR over the forecast period to reach US $1,634.50 million by 2027. Cialis (Tadalafil) segment represented US $147.10 million opportunity over 2019-2021 and estimated to create US $605.57 million opportunity in 2027 over 2021.

Levitra/Staxyn (vardenafil)

Levitra/Staxyn (vardenafil) segment was valued at US $471.41 million in 2019 and is projected to grow at 7.10% CAGR over the forecast period to reach US $873.77 million by 2027. Levitra/Staxyn (vardenafil) segment represented US $78.63 million opportunity over 2019-2021 and estimated to create US $323.72 million opportunity in 2027 over 2021.

Stendra/Spedra (avanafil)

Stendra/Spedra (avanafil) segment was valued at US $320.37 million in 2019 and is projected to grow at 7.10% CAGR over the forecast period to reach US $593.81 million by 2027. Stendra/Spedra (avanafil) segment represented US $53.44 million opportunity over 2019-2021 and estimated to create US $220.00 million opportunity in 2027 over 2021.

Zydena (udenafil)

Zydena (udenafil) segment was valued at US $226.48 million in 2019 and is projected to grow at 7.10% CAGR over the forecast period to reach US $419.78 million by 2027. Zydena (udenafil) segment represented US $37.78 million opportunity over 2019-2021 and estimated to create US $155.52 million opportunity in 2027 over 2021.

Vitaros (Alprostadil Cream)

Vitaros (Alprostadil Cream) segment was valued at US $67.53 million in 2019 and is projected to grow at 7.10% CAGR over the forecast period to reach US $125.17 million by 2027. Vitaros (Alprostadil Cream) segment represented US $11.26 million opportunity over 2019-2021 and estimated to create US $46.37 million opportunity in 2027 over 2021.

Other Products

Other Products segment was valued at US $112.83 million in 2019 and is projected to grow at 7.10% CAGR over the forecast period to reach US $209.14 million by 2027. Other Products segment represented US $18.82 million opportunity over 2019-2021 and estimated to create US $77.48 million opportunity in 2027 over 2021.

Distribution Channel

Introduction

In 2021, Hospital Pharmacies segment has the highest revenue of US $1,640.07 million and is expected to grow at CAGR of 7.10% by 2027 Hospital Pharmacies segment has highest cagr growth of 7.10%.

Hospital Pharmacies

Hospital Pharmacies segment was valued at US $1,405.60 million in 2019 and is projected to grow at 7.10% CAGR over the forecast period to reach US $2,605.31 million by 2027. Hospital Pharmacies segment represented US $234.46 million opportunity over 2019-2021 and estimated to create US $965.24 million opportunity in 2027 over 2021.

Retail Pharmacies

Retail Pharmacies segment was valued at US $1,064.38 million in 2019 and is projected to grow at 7.10% CAGR over the forecast period to reach US $1,972.85 million by 2027. Retail Pharmacies segment represented US $177.55 million opportunity over 2019-2021 and estimated to create US $730.92 million opportunity in 2027 over 2021.

Online Pharmacies

Online Pharmacies segment was valued at US $939.14 million in 2019 and is projected to grow at 7.10% CAGR over the forecast period to reach US $1,740.72 million by 2027. Online Pharmacies segment represented US $156.66 million opportunity over 2019-2021 and estimated to create US $644.92 million opportunity in 2027 over 2021.